Dr Steg has been a Professor of Cardiology at Université Paris - Diderot since 1994. He is also Professor at the National Heart and Lung Institute, Imperial College, London, UK. He works as an interventional cardiologist and is Director of the Coronary Care Unit of Hôpital Bichat, in Paris, France. He is also Director of the “Clinical Research in Atherothrombosis” Research Team, which belongs to INSERM U-1148, Paris and a co-coordinator of the Département Hospitalo-Universitaire FIRE (Fibrosis, Inflammation and REmodeling) affiliated with INSERM, Université Paris-Diderot and Assistance Publique – Hôpitaux de Paris. He is chair of the FACT (French Alliance for Cardiovascular clinical Trials) academic research network.
Dr Steg’s research interests are in the field of coronary artery disease. He is a former member of the Board of the French Society of Cardiology, an honorary member of the Institut Universitaire de France, and received the silver medal of the European Society of Cardiology in 2011.
Dr Steg led the TAO and EUROMAX trials and is currently chairing or co-chairing several trials or registries, such as ODYSSEY-CV Outcomes, CLARIFY, THEMIS. Dr Steg has authored more than 650 articles in peer-reviewed international journals. He is a member of the editorial boards for Circulation, Circulation: Cardiovascular Interventions, the European Heart Journal, and the European Heart Journal – Cardiovascular Pharmacotherapy. He is deputy editor for the Journal of the American College of Cardiology. Finally, Dr Steg was co-chair of the task force in charge of the 2012 ESC Guidelines for management of ST-segment elevation myocardial infarction.
et al., 2019, Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry, European Heart Journal, ISSN:0195-668X, Pages:1-10
et al., 2019, Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial., Eur Heart J, Vol:40, Pages:2801-2809
et al., 2019, EvaluatioN of ApiXaban in strOke and systemic embolism prevention in patients with non-valvular atrial fibrillation in clinical practice Setting in France, rationale and design of the NAXOS: SNIIRAM study, Clinical Cardiology, ISSN:0160-9289
et al., 2019, Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia, New England Journal of Medicine, Vol:380, ISSN:0028-4793, Pages:11-22
et al., 2018, Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54, Scientific Sessions and Resuscitation Science Symposium of the American-Heart-Association (AHA), WILEY, ISSN:2047-9980